We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Section: bioprocessing and biological engineering gene fragment polymerization for increased yield of recombinant HIV fusion inhibitor enfuvirtide.
- Authors
Gudipudi, Anil; Bajji, Chitra; Kosana, Ravikanth; Panati, Kalpana; Lomada, Dakshayani; Arva Tatireddigari, Venkat; Narala, Venkata
- Abstract
Fuzeon (Enfuvirtide, T20) is the first fusion inhibitor approved by the FDA of the USA for the treatment of HIV/AIDS in combination with other anti-retroviral drugs. Enfuvirtide is a synthetic peptide that blocks the entry of HIV into healthy host CD cells, which requires very high (90 mg twice daily) therapeutic doses. To increase the yield of Enfuvirtide, a gene polymerization strategy was introduced and recombinant T20 (rT20) was expressed in Escherichia coli as a five copy repeat polypeptide with a histidine-tag. The five copy rT20 was purified by Ni-affinity chromatography and cleaved to single rT20 units by cyanogen bromide. Finally, single rT20 units were purified by reversed phase chromatography giving a yield (400 mg/l) with a purity >95 %, which exhibited specific biological activity similar to Fuzeon.
- Subjects
ENFUVIRTIDE (Drug); POLYMERIZATION research; CHEMICAL yield; ESCHERICHIA coli; POLYPEPTIDES; AFFINITY chromatography; CYANOGEN bromide
- Publication
Biotechnology Letters, 2014, Vol 36, Issue 9, p1761
- ISSN
0141-5492
- Publication type
Article
- DOI
10.1007/s10529-014-1556-8